It’s fast acting.
Finding the right preventive treatment for migraines often involves lengthy trial-and-error processes. However, the daily medication Qulipta (atogepant), approved in 2021, offers rapid relief, according to findings published in Neurology. Clinical trials revealed that the drug significantly reduces the risk of migraines from the very first day of use, providing a promising option for those seeking quick and effective solutions.
Qulipta works by blocking calcitonin gene-related peptide (CGRP), a protein linked to migraine attacks. The analysis of three major trials—ADVANCE, PROGRESS, and ELEVATE—showed that patients using the medication had a significantly lower risk of experiencing migraines on the first day compared to those on a placebo. For example, in the ADVANCE trial, only 12% of Qulipta users reported migraines on the first day, compared to 25% of those on a placebo.
Patients using Qulipta also reported less daily impairment from migraines and an improved quality of life compared to placebo users. This quick onset of effectiveness sets Qulipta apart from many existing treatments that can take weeks or months to show results, which often leads to frustration and discontinuation of use. Dr. Richard Lipton, a lead researcher, emphasized the importance of developing treatments that act swiftly to address this gap in care.
Despite its benefits, Qulipta’s high cost is a concern. A 30-day supply costs approximately $1,160 without insurance or discounts, which is significantly higher than older treatments like generic triptans, which can cost as little as $12 per month. While its effectiveness meets a critical need, affordability may limit access for many patients.
Overall, Qulipta represents an important advancement in migraine prevention, particularly for individuals whose lives and daily activities are heavily impacted by migraines. Its ability to act quickly and improve patients’ quality of life makes it a significant development in addressing this common and often disabling condition.
Discussion about this post